NeoGenomics, Inc. provided earnings guidance for the year 2022. The company now expects that full year revenue will be flat to up modestly on a year-over-year basis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.58 USD | -1.09% |
|
-2.09% | -16.07% |
05-28 | NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO | CI |
05-02 | North American Morning Briefing : Stock Futures -3- | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.07% | 1.73B | |
-19.54% | 8.46B | |
+71.50% | 4.41B | |
+12.77% | 2.88B | |
-57.49% | 1.7B | |
-16.46% | 1.5B | |
+21.44% | 1.25B | |
-49.06% | 1.03B | |
+15.31% | 968M | |
-16.56% | 878M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- Neogenomics, Inc. Provides Earnings Guidance for the Year 2022